Objectives. The purpose of the present study was to examine the expression of the endothelial-type nitric oxide synthase (NOS III) and the inducible-type NOS (NOS II) in human myocardium and their regulation in heart failure from patients with different etiologies.
Nitric oxide (NO) is enzymatically formed from L-arginine by three isoforms of NO synthase (NOS) (1) . Whereas the neuronal-type NOS I and the endothelial-type NOS III are constitutive low-output, Ca 2ϩ -activated enzymes, the cytokineinducible NOS II is a Ca 2ϩ -independent high-capacity enzyme. There is evidence that NO reduces myocardial contractility by different mechanisms (2-14, reviewed in 15) . This has been shown for high concentrations of NO, as produced by the inducible isoform of NOS (NOS II). Interestingly, also physiologic concentrations of NO, as produced by Ca 2ϩ -dependent isoforms of NOS, seem to be sufficient for this effect (15) . Nevertheless, the physiologic as well as the pathophysiologic role of L-arginine-derived NO in regulating myocardial contractility remain controversial (16 -20, reviewed in 21) .
One uncertainty refers to heart failure. Congestive heart failure is characterized by contractile dysfunctions, for example, diminished contractile response to beta-adrenergic agonists (22) , attenuated force-frequency-relationship (23) and various morphologic as well as cellular abnormalities, for example, hypertrophy (24) , apoptosis (25) and changes in calcium handling (26) . Some of these defects have been proposed to be associated with a stimulation of the L-arginine-NO system (11, 27) . However, there is controversy as to whether NOS II is expressed in the myocardium of failing human hearts. De Belder et al. (28, 29) reported increased enzyme activity of a Ca 2ϩ -independent NOS in the myocardium of patients with dilated cardiomyopathy, myocarditis and postpartum cardiomyopathy, but not in ischemic or valvular heart disease. Others demonstrated NOS II mRNA and immunoreactivity in hearts from patients with dilated cardiomyopathy (30 -32) , but also in ischemic and valvular heart disease (30) . In previous studies we have found NOS II immunoreac-tive protein only in septic hearts, but not in other forms of cardiomyopathy (33) . In the current study we confirm the lack of significant expression of NOS II mRNA and protein in human hearts with different forms of cardiomyopathy. Since there are no reports concerning the expression of NOS III in ventricular myocardium from patients with heart failure, we investigated additionally NOS III gene expression. Nitric oxide synthase protein has been demonstrated in atrial tissue from nonfailing (NF) human hearts (34) and rat ventricular cardiomyocytes (9, 10) . Recent studies demonstrated that in vivo gene transfection of NOS III in cardiomyocytes caused apoptosislike cell death, thereby mimicking the morphologic features of acute myocarditis or ischemic injury (27) . Moreover, given the modulating activity of NOS III-derived NO on the inotropic effects of beta-blockers and cholinergic agonists (8 -12) as well as the force-frequency-relation (13, 14) , we hypothesized that an increased expression of the endothelial-type NOS III may occur in human heart failure and contribute to the contractile and/or morphologic abnormalities.
Here we report an increased expression of NOS III mRNA and protein in various forms of human cardiomyopathy, using RNase protection analysis, Western blotting and immunohistochemistry.
Methods
Myocardial tissue. Failing human hearts were obtained from patients undergoing heart transplantation because of end-stage heart failure due to idiopathic dilated cardiomyopathy (dCMP, n ϭ 14) ischemic cardiomyopathy (iCMP, n ϭ 9) or postmyocarditis cardiomyopathy (mCMP, n ϭ 7). Criteria used for the differentiation between iCMP and mCMP were 1) anamnestic or histologic evidence for myocarditis or the presence of specific antibody titers in the serum and 2) the lack of coronary stenosis as confirmed by left heart catheterization. All patients were classified as New York Heart Association class IV with markedly abnormal pretransplant hemodynamics. Mean cardiac index was 1.85 Ϯ 0. 13 Written informed consent was taken from all patients or the family of prospective heart donors before cardiectomy. Tissue samples from the free wall of left ventricles (dCMP n ϭ 14; iCMP n ϭ 9; mCMP n ϭ 3; NF n ϭ 5) or right ventricles (mCMP n ϭ 4) were obtained at the time of explantation and rapidly frozen in liquid nitrogen. Care was taken not to take scarred, fibrotic or adiposed tissue; endocard and epicard or great vessels were removed. Tissue samples were stored at Ϫ80°C until further use.
RNA preparation and RNase protection assay. Total RNA was extracted from left ventricular tissue samples (0.5 to 1.0 g) by acid guanidium thiocyanate-phenol-chloroform extraction, as described previously (35) . RNA yields were 0.76 Ϯ 0.08 (NF), 0.68 Ϯ 0.04 (dCMP), 0.68 Ϯ 0.05 (iCMP) and 0.67 Ϯ 0.05 (mCMP) g/mg tissue. The average OD 260/280 was 1.95 (n ϭ 35). All RNA preparations were checked in 1% formaldehyde containing agarose gels. RNase protection assays were performed with RPA II kit (Ambion Inc., Austin, Texas) according to the manufacturer's protocol with minor modifications. Plasmids (pBluescript) containing human NOS II or NOS III cDNA-fragments were gifts from D.A. Geller (36; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania) and P.A. Marsden (37; Department of Surgery, University of Toronto, Toronto, Ontario, Canada). Antisense-RNA probes for NOS II, NOS III and Gs␣ were generated by in vitro transcription of 0.5 g linearized plasmid DNA (restriction of NOS II with Nae I and NOS III with Sma I) using T3 or T7 RNA polymerase. The reaction was performed in 1ϫ transcription buffer (Ambion Inc.) containing ATP, GTP, CTP (20 nmol/L, each), 50 Ci 32 P-UTP (800 Ci/mM; NEN, Dreieich, Germany), RNase inhibitor (40 U; Promega, Madison, Wisconsin) and dithiothreitol (10 mmol/L) in a total volume of 20 l for for 2 h at 25°C. After transcription, the reaction mix was treated with RNAse-free DNase I (20 U, Boehringer, Mannheim, Germany) for 15 min at 37°C. Subsequently, the antisense-RNA probes were purified by 8M urea gel electrophoresis (Long Ranger Gel, AT Biochem, Malvern, Pennsylvania). The respective bands were cut out with sterile razor blades under autoradiographic control, and RNA-probes were eluted by overnight incubation in elution buffer (Ambion Inc.) at 37°C. 32 P-labeled NOS II and NOS III antisense-RNA probes (50,000 disintegrations per minute [dpm], each) and Gs␣ antisense-RNA probe (7,500 dpm) were hybridized (hyAbbreviations and Acronyms dCMP ϭ idiopathic dilated cardiomyopathy iCMP ϭ ischemic cardiomyopathy mCMP ϭ postmyocarditis cardiomyopathy NF ϭ nonfailing NO ϭ nitric oxide NOS ϭ nitric oxide synthase NOS II ϭ inducible-type nitric oxide synthase NOS III ϭ constitutive endothelial-type nitric oxide synthase RT-PCR ϭ reverse transcriptase-polymerase chain reaction bridization buffer from Ambion Inc.) with 10 to 30 g of total RNA at 45°C overnight. The reaction mix was digested with RNase A/T 1 (5 g/ml and 100 U/ml, respectively) for 30 min at 37°C. Incubations of 32 P-labeled antisense-probes (50,000 dpm each) with tRNA were treated with RNases and served as negative controls, others (2,000 dpm each) were treated with solution Dx (Ambion Inc.) and served as positive controls. After addition of solution Dx, the samples were incubated for 30 min at Ϫ80°C and then centrifuged at 15,000 ϫ g (15 min, 4°C). The pellets were resuspended in formamide containing loading buffer (Ambion Inc.), denatured for 5 min at 95°C and loaded onto a 5% polyacrylamide gel containing 8M urea. Autoradiography of dried gels was performed at Ϫ20°C for 5 to 10 days.
Densitometric analyses of RNase protection assays were performed using a Phosphoimager (ZERO-Dscan, Scanalytics, Billerica, Massachusetts). Resulting densities and pixel values were analyzed by ZERO-Dscan software. Five-point calibration curves were constructed with specific sense-orientated RNAs (0.5 to 20 pg) for NOS II and NOS III that were supplemented with 20 g tRNA (Fig. 1 ). Sense-RNAs were produced by in vitro transcription in the presence of trace amounts (1:10,000) of 32 P-UTP to monitor the incorporation efficiency. Sizes of NOS II and NOS III sense-RNA were 2,121 nt for NOS II (2,060 nt cDNA plus 61 nt multiple cloning site [MCS]) and 2,282 nt for NOS III (2,180 nt cDNA plus 102 nt MCS), respectively. The reaction usually yielded between 5 and 10 g RNA that were purified by gel filtration on Sephadex G-50, diluted to 100 pg/ml in TE/0.5% SDS and stored at Ϫ80°C.
Pixel values of the NOS II and NOS III calibration curves were fitted by linear regression. Density units of the signals for protected fragments were referred to the respective calibration curve and mRNA concentrations expressed as pg/g total RNA. Since the size of NOS III sense-RNA (2.2 kb) was about half of the native NOS III mRNA (about 4.4 kb), the calculated yields were multiplied by the factor 2. To exclude minor differences in RNA-loading, NOS signal intensities were corrected by the signal for Gs␣ mRNA which has been demonstrated to be unchanged in human heart failure (38) . To obtain comparable counts we used labeled antisense probes of 7,500 dpm for Gs␣ (specific activity ϳ1 ϫ 10 8 dpm/g) compared to 50,000 dpm for NOS II or NOS III (specific activity ϳ2 ϫ 10 9 dpm/g). The mean of all Gs␣ pixel values on one gel was divided by the individual Gs␣ pixel value, yielding a factor that expressed deviations from the average and thereby loading differences. This factor was multiplied with the respective NOS-mRNA value. Factors were 1.10 Ϯ 0.12 (NF, n ϭ 5), 1.19 Ϯ 0.08 (dCMP, n ϭ 14), 1.14 Ϯ 0.11 (iCMP, n ϭ 9) and 1.16 Ϯ 0.16 (mCMP, n ϭ 7). Correction by this procedure did not alter the magnitude or the direction of the results, but lowered the standard deviation.
Protein extraction and Western blotting. Tissue samples from human heart transplants were homogenized in three volumes of an ice-cold Tris-buffer (50 mmol/L Tris-HCl pH 7.5, 0.5 mmol/L EGTA, 0.5 mmol/L EDTA, 2 mmol/L dithiothreitol, 7 mmol/L glutathione, 10% [v/v] glycerol, 10 g/ml pepstatin A, 20 U/l aprotinin, 10 g/ml leupeptin and 0.2 mmol/L PMSF) using an Ultra-Turrax (Kinematica A6, LittauLuzern, Suisse). For solubilization of membrane-bound proteins, homogenates were treated with the detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfonate (CHAPS) at a final concentration of 20 mmol/L (rotating shaker, 20 min at 4°). The CHAPS extracts were centrifuged at 160,000 ϫ g. Protein contents were measured in the resulting supernatants with the micro-adapted Bradford (39) assay. Proteins were separated by denaturing discontinuous polyacrylamide gel electrophoresis using 7.5% resolving gels and blotted onto nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) in a semi-dry electrophoretic transfer cell (Trans-Blot, Bio-Rad, Munich, Germany). Blots were blocked for 60 min with 3% (w/v) bovine serum albumin and 0.05% (w/v) Tween 20 in TBS (10 mmol/L Tris/HCl, pH 7.4, in 0.9%, w/v, NaCl). They were then incubated for 90 min at room temperature with the primary antibody in TBS containing 0.5% (w/v) gelatin and 0.05% (w/v) Tween 20. The following primary antibodies were used: a monoclonal anti-NOS II antibody (1:1,500) and a polyclonal anti-NOS III antibody (1:500), purchased from Transduction Laboratories (Lexington, Kentucky), and a monoclonal anti-beta-tubulin antibody (1:500, Sigma Bio Sciences, Deisenhofen, Germany). Blots were washed in TBS/gelatin/Tween and immunoreactive pro- teins were visualized with NBT/X-phosphate (4-nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate) after a 60-min incubation with the secondary antibody conjugated to alkaline phosphatase.
NOS III immunohistochemistry. Ten-micrometer sections were prepared using a cryostat. Sections were thaw-mounted onto poly-L-lysine-coated glass slides (Sigma), air-dried and slightly fixed in ice-cold acetone for 5 to 10 s. First, sections were washed in PBS for 10 min, and endogenous peroxidase was blocked by incubation for 30 min in a freshly prepared solution of 40% (v/v) methanol and 0.6% (v/v) H 2 O 2 in PBS. Blocking of endogenous biotin or biotin-binding proteins was performed with a commercially available avidin/biotin-kit (Camon, Wiesbaden, Germany). Thereafter, sections were washed for 10 min in incubation medium (4% dry-milk powder in PBS) and incubated with a 10% solution of normal serum (Camon) from the species in which the secondary antibody was generated. Incubation with the primary polyclonal anti-NOS III antibody (Transduction Laboratories, 1:50) was performed overnight at 4°C; sections were washed in incubation medium and exposed to the secondary biotinylated antibody (Camon, 1:100) for 60 min at room temperature. This was followed by at least two washes in PBS and incubation with a 1:100 dilution of the streptavidin-biotinylated horseradish peroxidase complex (Amersham, Buchler, Germany) in PBS for 20 min. After repeated washing with PBS, the chromogen-reaction was performed by the use of 3.3Ј-diaminobenzidine (Sigma) according to the instructions of the manufacturer. The sections were washed in distilled water, counterstained with Mayer's acid hemalaum, mounted in glycerol gelatin and coverslipped. 
Results
RNase protection analysis. The in vitro transcription of linearized plasmid DNA and subsequent purification of the products resulted in homogenous bands of 32 P-labeled antisense-RNA probes for NOS II (619 nt), NOS III (505 nt) and Gs␣ (403 nt) RNAs (Fig. 2) . Hybridization of these probes with the respective sense-RNAs gave protected fragments of 587 nt for NOS II (570 ϩ 17 nt MCS) and 462 nt for NOS III (433 ϩ 29 nt MCS; Fig. 2, lane 6) . Hybridization with total RNA from ventricular tissue of NF or failing human hearts resulted in protected fragments of 570 nt for NOS II, 433 nt for NOS III and two fragments of 353 nt and 338 nt for Gs␣ (Fig.  2, lanes 8 to 22) . As both antisense-probes and sense-RNAs contained portions of the multiple cloning site, they differed in their size from the respective protected fragments of total RNA.
Quantification of NOS III-specific mRNA in NF human hearts revealed 0.42 Ϯ 0.04 pg/g total RNA (n ϭ 5, Fig. 3A ). Compared to NF hearts, NOS III-mRNA levels were increased in failing human hearts to ϳ180% (0.77 Ϯ 0.09, n ϭ 14; dCMP), ϳ200% (0.83 Ϯ 0.19, n ϭ 9; iCMP) and ϳ210% (0.88 Ϯ 0.04, n ϭ 7; mCMP; Fig. 3A) . Nitric oxide synthasemRNA levels tended to be increased also in iCMP, but this effect did not reach significance. This is due to the unequal distribution (nonparametric distribution) of the individual values as demonstrated in Fig. 3B . Inducible-type NO-mRNA expression was detected only in 7% (two out of 30, one dCMP and one mCMP) of failing human hearts and was not detected in NF hearts. On the other hand, in stimulated human dCMP (10,12,18,20), iCMP (9,11,14,17) or mCMP  (13,19,21,22) hepatocytes (300 ng/ml LPS and 3 U/ml IFN-␥, 18 h) the NOS II antisense-probe hybridized to a single band of the expected size for the NOS II, indicating that NOS II-mRNA expression was detectable with the methods (Fig. 2, lane 23) .
Western blotting and immunohistochemistry. On Western blots, the monoclonal anti-NOS II antibody selectively stained a protein of 130 kDa in homogenates of lipopolysaccharideinduced RAW 264.7 macrophages (positive control for NOS II; Fig. 4, upper panel) . However, no band was detected by this antibody in homogenates from NF or failing human hearts (even though more protein was loaded). In contrast, significant NOS III immunoreactivity was found in NF and failing myocardium. This protein comigrated with a 135 kDa protein from the particulate fraction of human EA.hy 926 endothelial cells (40; positive control for NOS III; Fig. 4, lower panel) . When the NOS III immunoreactive signal from the heart samples was normalized using the costained band of constitutively expressed beta-tubulin, failing hearts showed an increased NOS III protein expression relative to NF hearts. The increase in iCMP was 131% of control. The strongest augmentation in NOS III protein was detected in samples from patients with mCMP yielding to 221% of control (data are means of four observations). As expected, in immunohistochemical experiments, the polyclonal anti-NOS III antibody clearly labeled the endothelium of blood vessels in the different heart specimens. Staining intensities of the endothelium of cardiac blood vessels were comparable in samples from NF and failing hearts (Fig. 5,  panel A) . Also in human cardiomyocytes from NF hearts, a moderate NOS III-immunoreactivity was detected (Fig. 5,  panel B) . Moreover, this immunoreactivity was markedly enhanced in cardiomyocytes from failing hearts. No apparent differences in staining intensities in the cardiomyocytes were detected between the different forms of cardiomyopathy. 
Discussion
In the current study we demonstrate an increase in the expression of NOS III mRNA in left ventricular tissue from failing compared with NF human hearts as determined by quantitative RNase protection assay. Immunohistochemistry with a selective antibody to NOS III showed no obvious differences in the staining of the endothelium of cardiac blood vessels from NF and failing hearts. However, NOS IIIimmunoreactivity was significantly more intense in cardiomyocytes from failing compared to NF hearts. Recently, the expression of NOS III mRNA has been demonstrated in NF human atrial tissue obtained from donor hearts being used for cardiac transplantation (34) . However, there are no reports on NOS III expression in human heart failure, although there is recent evidence for its involvement in animal models of heart failure (41-43).
NOS II expression.
Alterations in NOS II expression have been reported in human heart failure (30 -32) . In the present study, only 2 of 30 failing human hearts showed low expression of NOS II mRNA as detected by quantitative RNase protection analysis. In NF hearts NOS II mRNA was totally absent. Similarly, in Western blots, NOS II immunoreactivity was detected neither in failing nor in NF hearts. This confirms and extends our recent findings on different types of heart failure demonstrating significant NOS II protein expression exclusively in failing hearts from patients with sepsis (33) . In contrast, others found expression of NOS II in other types of human heart failure (30 -32) . De Belder et al. (28, 29) reported significant Ca 2ϩ -independent NOS activity in endomyocardial biopsies from patients with dCMP, mCMP and postpartum cardiomyopathy (suggesting the presence of NOS II), but not in patients with ischemic or valvular heart disease. However, Incubations with a rabbit nonimmune serum gave no staining in the myocardium (Neg, negative control, slice object: mCMP). The average diameter of cardiomyocytes from failing hearts was increased compared to NF hearts. Magnification in A and B 400ϫ. Photomicrographs are representative of at least four experiments with identical results. measurement of the Ca 2ϩ -dependence of NOS enzymatic activity does not allow an unequivocal isoform identification. Previous immunohistochemical studies have detected strong immunoreactivity for NOS II in myocytes from dCMP hearts, but only moderately intense staining in myocytes from patients with iCMP and no signal in hypertrophic or NF myocardium (31, 32) . Haywood et al. (30) , performing reverse transcriptionpolymerase chain reaction (RT-PCR), described that NOS II occurred in 67% of patients with dCMP, 59% of patients with iCMP and in 100% of patients with valvular heart disease. Similarly, Satoh et al. (32) observed NOS II mRNA in 54% of dCMP patients, but not in patients with hypertrophic cardiomyopathy also using RT-PCR. These data indicate that NOS II is not expressed in all patients with the same etiology and in addition varies between different types of heart failure. Thus, the apparent differences between the present findings and previous findings of others can be explained by the different methods used. Reverse transcription-polymerase chain reaction is a sensitive method to detect trace amounts of mRNA (1 mole), whereas RNase protection analysis allows the measurement of biologically relevant concentrations of mRNA (in the range of 0.1 pg). Hence, trace amounts of NOS II mRNA present in some failing hearts and detected by RT-PCR may have escaped our RNase protection assays. Furthermore, it is conceivable that NOS II expression is different in right and left ventricular tissue. In the present study we used mainly (26 of 30 failing hearts) left ventricular tissue, whereas others (28 -32) investigated NOS II expression in right ventricular tissue.
NOS III expression. We now demonstrate NOS III mRNA and protein both in failing and NF myocardium. We found NOS III mRNA levels increased in failing hearts: dCMP ϳ180%, iCMP ϳ200% and mCMP ϳ210%, compared with NF hearts (100%). Accordingly, on Western blots increased expression of NOS III protein was detected in failing hearts as compared to NF hearts. One may hypothesize that such an increase results from an enhanced expression in endothelial cells. However, the immunohistochemical results argue against this interpretation. We found similar NOS III staining intensities in the endothelium of blood vessels from failing and NF hearts. In contrast, NOS III immunoreactivity in normal myocardium was clearly intensified in the cardiomyocytes from failing hearts. Thus, the recently reported elevated plasma nitrate levels in patients with heart failure (44) may be explained in part by the increased NOS III expression in cardiomyocytes. However, the finding of elevated plasma levels is not undisputed, since others demonstrated decreased NO production in coronary microvessels from failing human hearts (45) . Furthermore, in studying a dog model for heart failure, Zaho et al. (46) reported reduced expression of NOS III mRNA and protein in the aorta of these dogs.
Functional role of NOS III upregulation. Nitric oxide production by NOS III within the cardiomyocyte could exert an effect on myocardial contractility. Recent reports demonstrated that NO formed by NOS III reduced inotropic responsiveness to beta-blockers (8, 9, 11) and force-frequency relation (13, 14) in the heart, probably by acting via the cGMP signal cascade to modulate L-type calcium channels (9, (47) (48) (49) . Moreover, it has been shown that the beta-adrenergic hyporesponsiveness mediated by NO is augmented in an animal model of heart failure (50) . Thus, it is conceivable that an increased NO-formation due to elevated NOS III expression in the failing myocardium is involved in the diminished responsiveness to beta-blockers and/or the attenuated myocardial forcefrequency relation in human heart failure. However, considerable efforts by others failed to support the abovementioned conclusions (17) (18) (19) (20) (21) . The present finding of an increased NOS III expression in cardiomyocytes from failing hearts may be of pathophysiologic relevance. Recently, it has been demonstrated that in vivo gene transfection of NOS III into cardiomyocytes caused apoptosislike cell death and that these morphologic features mimicked acute myocarditis or ischemic injury (27) . Therefore, the increased NOS III expression in failing hearts may contribute to the morphologic alterations seen under these conditions.
Conclusion. We conclude that the increased NOS III expression in ventricular myocardium of failing human hearts may contribute to the contractile dysfunction observed in heart failure and/or may play a role in morphologic alterations such as hypertrophy and apoptosis of cardiomyocytes.
